Personalized Approaches to Antiplatelet Treatment for Cardiovascular Diseases: An Umbrella Review

Keyphrases

• Cardiovascular Disease 100%
• Antiplatelet Therapy 100%
• Personalized Approach 100%
• Antiplatelet Agents 100%
• Umbrella Review 100%
• Protective Effect 33%
• Risk Score 33%
• Risk Profile 33%
• Clinical Setting 33%
• Bleeding Events 33%
• Treatment Decisions 33%
• Dual Antiplatelet Therapy 33%
• Consensus Definition 33%
• Bleeding Risk 33%
• Secondary Prevention 33%
• Genetic Testing 33%
• Platelet Reactivity 33%
• Patient Morbidity 33%
• Myocardial Revascularization 33%
• Patient Mortality 33%
• Impact on Patients 33%
• Net Clinical Benefit 33%
• Risk Stratification System 33%
• Antithrombotic Strategies 33%
• P2Y12 Inhibitors 33%
• Therapy Intensity 33%
• Thrombotic Events 33%
• Factor Xa Inhibitors 33%
• Ischemic Risk 33%
• Cardiac Patients 33%
• Artificial Intelligence Tools 33%
• Antiplatelet Strategy 33%
• Antithrombotic Management 33%
• Dose Factor 33%
• Polyvascular Disease 33%
• Dual Pathway Inhibition 33%
• High Ischemic Risk 33%
• Platelet Function Tests 33%

Medicine and Dentistry

• Cardiovascular Disease 100%
• Antiplatelet 100%
• Umbrella Review 100%
• Antithrombotic 75%
• Antiplatelet Drug 75%
• Low Drug Dose 25%
• Monotherapy 25%
• Atherosclerosis 25%
• Bleeding 25%
• Risk Stratification 25%
• Platelet 25%
• Secondary Prevention 25%
• Thrombocyte Function 25%
• Heart Muscle Revascularization 25%
• Genetic Screening 25%
• Morbidity 25%
• Blood Clotting Factor 10a Inhibitor 25%
• Diseases 25%
• Artificial Intelligence 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Antiplatelet 100%
• Cardiovascular Disease 100%
• Anticoagulant Agent 75%
• Antithrombocytic Agent 75%
• Monotherapy 25%
• Bleeding 25%
• Atherosclerosis 25%
• Morbidity 25%
• Blood Clotting Factor 10a Inhibitor 25%
• Diseases 25%